What’s new

• Consolidated profit after tax rose to ₹979.64 lacs from ₹655.57 lacs in the prior year.
• Standalone revenue grew by 18% during the fiscal year.
• The board recommended a final dividend of ₹1.00 per share.

Why it matters

These results are a routine annual disclosure for a nano-cap firm. The lack of earnings surprises or strategic shifts suggests the company is tracking to its expected operational baseline.

What we’re watching

• Future revenue growth trends beyond the 18% standalone increase.
• Any changes to the dividend payout policy in subsequent years.
• Operational updates that could move the needle for a nano-cap entity.

The full read

Medicamen Biotech released its audited annual results for FY26. The numbers show a mix of growth and stability.

Standalone revenue grew by 18%, yet standalone net profit remained nearly flat at ₹940.87 lacs. On a consolidated basis, profit after tax climbed to ₹979.64 lacs from ₹655.57 lacs in the prior year. The board recommended a final dividend of ₹1.00 per share, maintaining the payout level from the previous year despite an increased share count.

This filing is a routine periodic disclosure. There were no unexpected earnings surprises, guidance changes, or material strategic developments. For a nano-cap pharmaceutical company, these figures represent scheduled information rather than market-moving news. It is a quiet year.

Primary source: BSE · NSE